Pierre Denayer

Human thyroglobulin reference material (CRM 457). 2nd Part: Physicochemical characterization and certification.

Ulla Feldt‐Rasmussen, Christos Profilis, Emile Colinet et al. · PubMed · 1996 · 67 citations

Immunocytochemical Technique, Laboratory Immunology, Immunology +19

Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity.

Ulla Feldt‐Rasmussen, Christos Profilis, E Colinet et al. · PubMed · 1996 · 57 citations

Histocompatibility, Immunocytochemical Technique, Immunology +19

ACUTE ENDOCRINE PROFILE OF SULPIRIDE IN THE HUMAN*

M. L’Hermite, Pierre Denayer, J. Golstein et al. · Clinical Endocrinology · 1978 · 29 citations · Full text

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

Vincent Van Pesch, E Bartholomé, Véronique Bissay et al. · Acta Neurologica Belgica · 2014 · 23 citations

Disease Progression, Systemic Scleroderma, Medicine +10

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

María Trojano, Helmut Butzkueven, Ludwig Kappos et al. · Multiple Sclerosis and Related Disorders · 2018 · 18 citations · Full text